Raffles Associates LP Lineage Cell Therapeutics, Inc. Transaction History

Raffles Associates LP

$85.5 Million
Q3 2025

A detailed history of Raffles Associates LP transactions in Lineage Cell Therapeutics, Inc. stock. As of the latest transaction made, Raffles Associates LP holds 5,387,788 shares of LCTX stock, worth $10.2 Million. This represents 10.91% of its overall portfolio holdings.

Number of Shares

5,387,788

Previous 5,392,088 0.08%

Holding current value

$10.2 Million

Previous $4.91 Million 89.97%

% of portfolio

10.91%

Previous 6.02%

17 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 14, 2025	SELL	$0.87 - $1.79 $3,741 - $7,697	-4,300 Reduced 0.08%	5,387,788 $9.32 Million
Q2 2025 Aug 15, 2025	SELL	$0.39 - $1.13 $97,500 - $282,500	-250,000 Reduced 4.43%	5,392,088 $4.91 Million
Q1 2025 May 15, 2025	BUY	$0.45 - $0.72 $67,500 - $108,000	150,000 Added 2.73%	5,642,088 $2.54 Million
Q4 2024 Feb 14, 2025	BUY	$0.5 - $0.95 $492,153 - $935,091	984,307 Added 21.84%	5,492,088 $2.75 Million
Q3 2024 Nov 14, 2024	BUY	$0.8 - $1.12 $120,000 - $168,000	150,000 Added 3.44%	4,507,781 $4.1 Million
Q2 2024 Aug 14, 2024	BUY	$0.89 - $1.47 $1.02 Million - $1.69 Million	1,147,800 Added 35.76%	4,357,781 $4.36 Million
Q1 2024 May 15, 2024	BUY	$0.86 - $1.48 $927,389 - $1.6 Million	1,078,360 Added 50.59%	3,209,981 $4.75 Million
Q4 2023 Feb 14, 2024	BUY	$0.91 - $1.35 $494,932 - $734,240	543,882 Added 34.26%	2,131,621 $2.32 Million
Q3 2023 Nov 14, 2023	SELL	$1.16 - $1.53 $11,600 - $15,300	-10,000 Reduced 0.63%	1,587,739 $1.87 Million
Q2 2023 Aug 14, 2023	BUY	$1.26 - $1.53 $76,599 - $93,013	60,793 Added 3.96%	1,597,739 $2.25 Million
Q4 2022 Feb 14, 2023	SELL	$1.02 - $1.5 $554,461 - $815,385	-543,590 Reduced 26.13%	1,536,946 $1.8 Million
Q3 2022 Nov 14, 2022	BUY	$1.13 - $1.77 $169,499 - $265,500	150,000 Added 7.77%	2,080,536 $2.35 Million
Q2 2022 Aug 15, 2022	BUY	$1.12 - $1.61 $699,373 - $1.01 Million	624,441 Added 47.81%	1,930,536 $3.05 Million
Q1 2022 May 16, 2022	BUY	$1.21 - $2.48 $922,631 - $1.89 Million	762,505 Added 140.27%	1,306,095 $2.01 Million
Q4 2021 Feb 15, 2022	BUY	$1.84 - $2.68 $828,000 - $1.21 Million	450,000 Added 480.82%	543,590 $1.33 Million
Q3 2021 Nov 16, 2021	BUY	$2.26 - $2.86 $112,999 - $143,000	50,000 Added 114.71%	93,590 $236,000
Q1 2021 May 17, 2021	BUY	$1.77 - $3.1 $77,154 - $135,129	43,590 New	43,590 $102,000

Others Institutions Holding LCTX

# of Institutions

128

Shares Held

96M

Call Options Held

251K

Put Options Held

50K

View Full List

About Lineage Cell Therapeutics, Inc.

Ticker LCTX
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 169,755,008
Market Cap $323M
Description
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-re...

More about LCTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Raffles Associates LP, based on Form 13F filings with the SEC.

News

Stay updated on Raffles Associates LP with notifications on news.

Account

Raffles Associates LP Lineage Cell Therapeutics, Inc. Transaction History